BlueCross BlueShield of Vermont
An Independent Licensee of the Blue Cross and Blue Shield Association.

BERLIN HQ
445 INDUSTRIAL LANE
BERLIN, VERMONT 05641

P.O. BOX 186
MONTPELIER
VT 05601-0186

800 247 2583
800 922 8778
802 255 4550

UPDATE: February 24, 2022, added M0222, M0223 and Q0222. Updated M0240, M0241, M0243-M0246, Q0240, Q0243, Q0244, and Q0245 to have a note advising product is not currently authorized by the FDA.

Below is the original notice with the updates.

January 12, 2021

Dear Home Infusion Therapy Provider and Outpatient Facilities:

When billing for COVID-19 monoclonal antibody treatment (injection), the antibody itself must also be reported on the claim. For antibody codes that are not eligible for reimbursement, the applicable antibody code must be reported, **no modifier** (DO NOT bill a modifier -SL) and a zero charge, or if your system is not capable of a zero charge, $0.01 can be billed.

Code	Effective Date	Description
M0220	12/8/21	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring.
M0221	12/8/21	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.

M0222	2/11/22	Intravenous injection, bebtelovimab, includes injection and post administration monitoring
M0223	2/11/22	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
M0240*	07/30/21	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses. **Note: This product is not currently authorized by the FDA**
M0241*	07/30/21	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID 19 public health emergency, subsequent repeat doses. **Note: This product is not currently authorized by the FDA**
M0243*	11/21/20	Administration of Infusion (Regeneron) **Note: This product is not currently authorized by the FDA**
M0244*	05/06/21	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitory the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID 19 public health emergency **Note: This product is not currently authorized by the FDA**
M0245*	02/09/21	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring (Eli Lilly) **Note: This product is not currently authorized by the FDA**
M0246*	05/06/21	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID 19 public health emergency **Note: This product is not currently authorized by the FDA**
M0247	05/26/21	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring.
M0248	05/26/21	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes

		a beneficiary's home that has been made provider-based to the hospital during the COVID 19 public health emergency
M0249	06/24/21	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age or older) with COVID 19 who are receiving systemic corticosteroids and require supplemental oxygen, no-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose
M0250	06/24/21	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age or older) with COVID 19 who are receiving systematic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose
Q0220	12/08/21	Infusion, tixagev and cilgav, 300 mg (AstraZeneca)
Q0222	2/11/22	Injection, bebtelovimab, 175 mg
Q0240*	07/30/21	Injection, casirivimab and imdevimab, 600 mg (Regeneron) **Note: This product is not currently authorized by the FDA**
Q0243*	11/21/20	Injection, casirivimab and imdevimab, 2400 mg (Regeneron) **Note: This product is not currently authorized by the FDA**
Q0244*	06/03/21	Injection, casirivimab and imdevimab, 1200 mg (Regeneron) **Note: This product is not currently authorized by the FDA**
Q0245*	02/09/21	Injection, bamlanivimab and etesevimab, 2100 mg (Eli Lilly) **Note: This product is not currently authorized by the FDA**
Q0247	05/26/21	**Injection, Sotrovimab, 500 mg** **NOTE: The government won't provide this drug for free.** Q0247 Crosswalks to the following NDC: 00173090186 under the Emergency Use Authorization (EUA)
Q0249	06/24/21	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age or older) with COVID 19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (CMO) only, 1mg **Note**: **The government won't provide this drug for free.** Q0249 Crosswalks to the following NDCs: 50242013501, 50242013601, & 50242013701 under the Emergency Use Authorization (EUA)

* On January 24, 2022, the FDA announced that, "due to the high frequency of the Omicron variant, this product isn't currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA". Retrieved from: https://www.fda.gov/media/143894/download

Over

The antibody treatment (injection) is not eligible for reimbursement (unless noted) as it is being supplied by the federal government.

If you have any questions regarding this notice, please feel free to contact your provider relations consultant via email at providerrelations@bcbsvt.com or by phone at (888) 449-0443 option 1. Business hours are Monday through Friday from 8 a.m. to 4:30 p.m., except holidays.

Sincerely,

Lou McLaren

Lou McLaren
Director, Provider Services